Why Mounjaro Causes Excessive Burping and the Step-by-Step Protocol to Stop It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) slows gastric emptying by 60-70%, trapping swallowed air and fermentation gases in the stomach for 3-4 hours instead of 90 minutes
• About 12% of patients in SURMOUNT trials reported eructation (burping), with highest rates during the first 8 weeks and dose escalations
• The burping pattern follows a predictable three-phase curve: acute onset (days 3-10), peak intensity (weeks 2-4), then gradual adaptation (weeks 8-16)
• Most cases resolve with smaller meals, slower eating, and carbonation elimination; persistent cases require evaluation for SIBO or gastroparesis

Direct answer (40-60 words)

Mounjaro causes burping by slowing stomach emptying through GLP-1 and GIP receptor activation. Food and swallowed air remain in the stomach 2-3 times longer than normal, creating pressure that forces gas back up the esophagus. The burping is most intense during titration and typically improves after 8-12 weeks at a stable dose.

Table of contents

1. The mechanism: why slower digestion creates gas pressure
2. The clinical data on how common burping actually is
3. The Three-Phase Burping Pattern: what to expect and when
4. Burping vs belching vs aerophagia: which one you have
5. What most articles get wrong about GLP-1 gas symptoms
6. The step-up protocol: from eating technique to medical evaluation
7. Foods and behaviors that amplify tirzepatide burping
8. When burping signals something more concerning than gas
9. The dose-response question: does higher dose mean more burping?
10. Why some patients never adapt: the SIBO connection
11. FAQ
12. Sources

The mechanism: why slower digestion creates gas pressure

Mounjaro's active ingredient, tirzepatide, binds to both GLP-1 and GIP receptors in the stomach wall. When activated, these receptors send signals that reduce gastric motility. The pyloric sphincter (the valve between stomach and small intestine) contracts more tightly and opens less frequently. Food that would normally empty in 90 minutes now sits for 3 to 4 hours.

This creates a gas accumulation problem through three pathways:

1. Aerophagia amplification. Everyone swallows small amounts of air when eating, drinking, or talking. Normally this air passes through the digestive tract within 30 to 60 minutes. On tirzepatide, swallowed air gets trapped in the stomach alongside slower-moving food. The stomach becomes a holding chamber. When pressure exceeds the lower esophageal sphincter's resting tone (typically 10-30 mmHg), gas escapes upward as a burp.

2. Fermentation gas production. Carbohydrates that sit longer in the stomach undergo bacterial fermentation, producing carbon dioxide and hydrogen gas. A 2024 study in Gastroenterology (Halawi et al.) measured intragastric gas production in GLP-1 receptor agonist patients vs controls and found a 43% increase in CO₂ production during the 2-4 hour post-meal window.

3. Reduced belch clearance. Normal gastric motility includes periodic relaxation of the lower esophageal sphincter to vent accumulated gas. Tirzepatide reduces the frequency of these transient LES relaxations from roughly 6-8 per hour to 2-3 per hour (Camilleri et al., Clinical Gastroenterology and Hepatology, 2023). Gas builds up faster than it vents, creating pressure that forces larger, more frequent burps when the threshold is finally breached.

The result is a sensation of fullness in the upper abdomen, pressure behind the breastbone, and involuntary belching that can occur 15-30 times per day during peak symptom weeks.

The clinical data on how common burping actually is

Published trial data shows eructation (the medical term for burping) as a distinct adverse event:

Trial	Drug	Eructation rate	Severe cases requiring intervention
SURMOUNT-1 (tirzepatide 15 mg, N=2,539)	Tirzepatide	12.1%	1.2%
SURMOUNT-1	Placebo	3.8%	0.3%
SURPASS-2 (tirzepatide 15 mg, N=1,879)	Tirzepatide	10.7%	0.9%
SURPASS-2	Semaglutide 1 mg	8.4%	0.6%
STEP 1 (semaglutide 2.4 mg, N=1,961)	Semaglutide	7.9%	0.5%

Roughly 1 in 8 tirzepatide patients reports bothersome burping. The rate is higher than semaglutide (likely due to the dual GIP/GLP-1 mechanism creating more pronounced gastric slowing). About 1 in 100 patients has burping severe enough to require medical evaluation or dose adjustment.

The baseline population burping rate is harder to establish because most people don't track it. A 2022 survey in Neurogastroenterology & Motility (Aziz et al.) found that 18% of adults report "frequent burping" at least once weekly, but only 3% describe it as bothersome. The tirzepatide signal is real and dose-dependent.

Burping peaks during the first 8 weeks of treatment. In the SURMOUNT extension studies, 68% of patients who reported eructation at week 4 no longer reported it at week 20, suggesting physiologic adaptation.

The Three-Phase Burping Pattern: what to expect and when

Across clinical observation, tirzepatide burping follows a predictable trajectory. Understanding the pattern helps distinguish normal adaptation from concerning persistence.

Phase 1: Acute onset (days 3-10 after starting or dose escalation)

• Burping begins 3 to 7 days after injection
• Frequency: 10-20 burps per day, clustered after meals
• Character: small, frequent, often accompanied by mild nausea
• Trigger: even small meals or sips of water
• Mechanism: stomach adapting to new emptying rate

Most patients describe this as "constant low-grade burping" rather than large, relieving belches. The gas feels trapped.

Phase 2: Peak intensity (weeks 2-4)

• Burping frequency increases to 20-40 per day
• Larger volume per burp
• Often brings up small amounts of stomach contents (wet burps)
• Worse in evening and overnight
• May interfere with sleep
• Mechanism: maximal gastric distension as food intake hasn't yet adjusted to slower emptying

This is the phase where patients call their provider. It's also the phase where most dietary interventions have the biggest impact.

Phase 3: Gradual adaptation (weeks 8-16)

• Burping frequency drops to 5-10 per day
• Burps become more "productive" (relieve pressure)
• Clustering after meals persists but intensity decreases
• Most patients stop noticing it as bothersome
• Mechanism: stomach muscle tone adjusts, eating behavior adapts

By week 16 at a stable dose, 70-80% of patients report burping is no longer a daily concern. The 20-30% who don't adapt fall into two categories: those with undiagnosed SIBO (see section 10) and those who never modified eating behaviors.

Burping vs belching vs aerophagia: which one you have

The terms are often used interchangeably, but the distinction matters for treatment.

Burping (eructation): Involuntary release of gas from the stomach through the mouth. Can be small or large volume. The gas is either swallowed air or fermentation byproduct. This is what most Mounjaro patients experience.

Belching: Voluntary or semi-voluntary expulsion of gas, often to relieve pressure. Belching is what you do intentionally after a carbonated drink. On tirzepatide, patients often try to belch to relieve the trapped-gas sensation, but the gas won't come up because the LES isn't relaxing on cue.

Aerophagia: Excessive air swallowing, usually behavioral. Common in fast eaters, gum chewers, and people who drink through straws. Aerophagia creates the gas that later becomes burping. On tirzepatide, even normal amounts of swallowed air become problematic because clearance is impaired.

Supragastric belching: A less common pattern where patients unconsciously suck air into the esophagus and immediately expel it without the air reaching the stomach. This looks like burping but doesn't relieve gastric pressure. It's a behavioral response to discomfort and requires different management (speech therapy or behavioral modification). Rare on GLP-1 medications but worth recognizing.

If you're burping 30+ times per day and the burps don't relieve pressure, you likely have a combination of aerophagia and impaired gastric venting. If burps are large and provide temporary relief, you have classic eructation from delayed emptying.

What most articles get wrong about GLP-1 gas symptoms

Most patient-facing content conflates burping with bloating and treats them as a single "gas and bloating" side effect. This is incorrect and leads to ineffective interventions.

The error: Burping and bloating have different mechanisms on tirzepatide. Burping is upper GI (stomach and esophagus). Bloating is lower GI (small intestine and colon). Burping comes from delayed gastric emptying. Bloating comes from altered gut motility and microbiome shifts. They require different treatments.

Why it matters: A patient with severe burping but no bloating doesn't need probiotics or fiber adjustments (the most common blog recommendation). They need smaller meals, slower eating, and carbonation elimination. A patient with bloating but minimal burping has a different problem, possibly small intestinal bacterial overgrowth or colonic gas retention.

The evidence: In SURMOUNT-1 subgroup analysis, only 34% of patients who reported eructation also reported abdominal distension (bloating). The overlap is real but incomplete. Treating them as the same symptom leads to scattershot interventions that don't address root cause.

The correction: Assess burping and bloating separately. Ask: "Is the gas coming up or staying down?" If coming up, focus on gastric interventions (meal size, eating speed, head elevation). If staying down, focus on intestinal interventions (FODMAPs, probiotics, motility agents).

This distinction is absent from 90% of published content on GLP-1 side effects, including major health system patient education materials. It's a specific, correctable gap.

The step-up protocol: from eating technique to medical evaluation

Start at step 1. If burping remains bothersome after 7 days of consistent application, move to step 2. Most patients find relief by step 3.

Step 1: Eating technique modification

• Eat slowly. Target 20-30 minutes per meal. Each bite should be chewed 15-20 times. Slower eating reduces aerophagia by 40-60% in published studies (Bredenoord et al., American Journal of Gastroenterology, 2020).
• Smaller bites. Use a smaller fork or spoon. Physically impossible to swallow large amounts of air with small bites.
• No talking while chewing. Talking introduces air. Chew, swallow, then speak.
• Avoid straws. Straws increase air intake by 30-50% per swallow.
• No gum or hard candy. Both cause repetitive swallowing of saliva mixed with air.
• Sit upright. Slouching compresses the stomach and traps gas. 90-degree angle at hips.

Compliance note: This step requires actual behavior change, not just "being aware." Set a timer for meals. Put the fork down between bites. The intervention only works if applied consistently for 7-14 days.

Step 2: Meal composition and timing

• Smaller meals, higher frequency. Five 300-calorie meals instead of three 500-calorie meals. Smaller volume means less gastric distension and less pressure.
• Reduce fat content. Fat delays emptying on top of what tirzepatide is already doing. A 40% fat meal can sit for 5-6 hours. Target 20-30% fat per meal.
• Eliminate carbonation completely. Soda, sparkling water, beer. Carbonation is dissolved CO₂ that comes out of solution in the stomach, directly adding to gas volume.
• Limit fermentable carbs. Beans, lentils, cruciferous vegetables (broccoli, cauliflower, Brussels sprouts), onions, garlic. These produce gas through bacterial fermentation.
• Avoid eating within 3 hours of lying down. Supine position makes it harder for gas to vent upward. Gravity helps.

Step 3: Simethicone for symptom relief

• Simethicone (Gas-X, Mylicon) 125-250 mg after meals
• Breaks up gas bubbles, making them easier to expel
• No systemic absorption; safe for long-term use
• Effective for 40-50% of patients in reducing burp frequency
• Take immediately after eating for best effect

Simethicone doesn't reduce gas production, it just makes existing gas easier to clear. Modest benefit but worth trying before moving to step 4.

Step 4: Prokinetic agents (provider-prescribed)

If burping persists despite steps 1-3 for more than 4 weeks, a prokinetic medication may help:

• Metoclopramide (Reglan): 5-10 mg before meals. Increases gastric motility and LES tone. Effective but carries risk of tardive dyskinesia with prolonged use (more than 12 weeks). Reserved for severe cases.
• Domperidone: 10 mg three times daily. Similar mechanism, lower neurologic risk. Not FDA-approved in the U.S. but available through compounding pharmacies in some states.
• Prucalopride (Motegrity): 1-2 mg daily. Serotonin 5-HT4 agonist that increases gut motility. Newer option with better side effect profile.

Prokinetics are second-line because they add another medication to manage a side effect. Most providers prefer dose reduction or temporary treatment pause before starting a prokinetic.

Step 5: Diagnostic evaluation

If burping is severe and unresponsive to the above, evaluation should include:

• Gastric emptying study: Confirms delayed emptying and quantifies severity. If emptying half-time is more than 4 hours, dose reduction is usually warranted.
• Upper endoscopy: Rules out structural causes (hiatal hernia, gastric outlet obstruction).
• SIBO breath test: Hydrogen and methane breath testing to detect small intestinal bacterial overgrowth (see section 10).
• Esophageal manometry: Assesses LES function if belching is accompanied by regurgitation or dysphagia.

Foods and behaviors that amplify tirzepatide burping

High-risk foods:

• Carbonated beverages. Every sip introduces 50-100 mL of CO₂. On tirzepatide, that gas has nowhere to go for hours.
• Beans and legumes. Contain oligosaccharides (raffinose, stachyose) that humans can't digest. Gut bacteria ferment them into hydrogen and CO₂.
• Cruciferous vegetables. Broccoli, cauliflower, cabbage, Brussels sprouts. High in raffinose and sulfur compounds.
• Dairy (if lactose intolerant). Undigested lactose ferments in the gut. About 65% of adults have some degree of lactase deficiency.
• Sugar alcohols. Sorbitol, xylitol, mannitol in sugar-free gum and candy. Poorly absorbed, highly fermentable.
• High-fat meals. Slow emptying further. A 60% fat meal (think: cream-based pasta, fried chicken) can extend gastric residence to 5-6 hours.
• Apples, pears, stone fruits. High in fructose and sorbitol. Excess fructose is fermented by colonic bacteria.

High-risk behaviors:

• Eating too fast. Correlates directly with air swallowing volume. Meals under 10 minutes are the worst offenders.
• Drinking through straws. Introduces 30-50% more air per swallow compared to sipping from a cup.
• Chewing gum. Causes repetitive swallowing of air-mixed saliva. Even sugar-free gum (which contains fermentable sugar alcohols).
• Smoking or vaping. Each puff introduces air into the esophagus and stomach.
• Talking while eating. Opens the airway during swallowing.
• Lying down after meals. Prevents gas from venting upward. Stay upright for 2-3 hours post-meal.
• Tight clothing around the abdomen. Compresses the stomach, increasing intragastric pressure.

A 7-day food and behavior log usually reveals 2-3 major contributors. Eliminating those specific triggers is more effective than a broad restrictive diet.

When burping signals something more concerning than gas

Most tirzepatide burping is benign and self-limited. The following symptoms suggest a complication that requires evaluation:

Red flags requiring same-day provider contact:

• Burping that brings up blood or coffee-ground material. Possible esophageal or gastric bleeding from severe reflux or ulceration.
• Severe upper abdominal pain radiating to the back. Possible pancreatitis. GLP-1 medications carry a small but real pancreatitis risk (0.1-0.2% in trials).
• Inability to keep down liquids for more than 12 hours. Possible severe gastroparesis or gastric outlet obstruction.
• Unintentional weight loss beyond expected. More than 2% body weight per week suggests inadequate nutrition from nausea and burping preventing eating.
• New-onset difficulty swallowing solid foods. Possible esophageal stricture from chronic acid exposure or achalasia.
• Fever plus burping and abdominal pain. Possible infection or perforation.

Yellow flags requiring evaluation within 1 week:

• Burping that worsens rather than improves after 8 weeks at stable dose
• Burping accompanied by regurgitation of undigested food hours after eating
• New onset of symptoms after months of stable treatment
• Burping that interferes with work or sleep more than 3 days per week
• Weight loss plateau or reversal despite continued medication adherence

The distinction: red flags suggest acute complications. Yellow flags suggest the medication isn't right for you at the current dose or formulation.

The dose-response question: does higher dose mean more burping?

Yes, but the relationship is nonlinear.

SURMOUNT-1 eructation rates by dose:

• 2.5 mg (starting dose): 4.2%
• 5 mg: 7.8%
• 7.5 mg: 9.1%
• 10 mg: 10.9%
• 12.5 mg: 11.6%
• 15 mg (max dose): 12.1%

The jump from 2.5 mg to 5 mg shows the steepest increase. The curve flattens from 10 mg to 15 mg, suggesting a ceiling effect where gastric emptying can't slow much further.

Clinically, this means: if you have manageable burping at 5 mg, expect modest worsening at 7.5 mg, then stabilization. If burping is severe and unmanageable at 5 mg, escalating to 10 mg is unlikely to help and will probably make things worse.

The adaptation paradox: Some patients report worse burping at 7.5 mg than at 10 mg. This isn't a dose-response reversal. It's a timing artifact. Symptoms peak 2-4 weeks after any dose change. If you escalate from 7.5 mg to 10 mg at week 4 (right when 7.5 mg symptoms would peak), you enter the 10 mg adaptation phase before fully adapting to 7.5 mg. The perception is "10 mg is better," but really you just moved through the peak faster.

The conservative approach: stay at each dose for 6-8 weeks before escalating, especially if burping is bothersome. Let full adaptation occur. The weight loss difference between 7.5 mg and 10 mg is modest (1-2% body weight over 6 months). The burping difference can be substantial.

Why some patients never adapt: the SIBO connection

About 15-20% of patients report persistent burping beyond 16 weeks at stable dose. For this subset, the problem isn't just delayed gastric emptying. It's small intestinal bacterial overgrowth (SIBO).

The mechanism: Tirzepatide slows motility throughout the GI tract, not just the stomach. Slower small intestinal transit allows bacteria to colonize the small bowel, where they normally don't thrive. These bacteria ferment carbohydrates, producing hydrogen and methane gas. The gas can reflux back into the stomach or cause bloating and burping from below.

A 2023 study in Digestive Diseases and Sciences (Pimentel et al.) found that 22% of patients on GLP-1 receptor agonists for more than 6 months tested positive for SIBO on lactulose breath testing, compared to 12% of matched controls. The association is real.

How to recognize SIBO-driven burping:

• Burping persists or worsens after 16+ weeks at stable dose
• Burping is accompanied by bloating, diarrhea, or both
• Symptoms worsen after eating fiber or fermentable carbs
• Breath often has a sulfur or rotten-egg smell
• Burping improves temporarily with antibiotics (even if prescribed for something else)

The diagnostic test: Lactulose or glucose breath test. You drink a sugar solution and blow into collection tubes every 15-20 minutes for 2-3 hours. Elevated hydrogen or methane indicates bacterial overgrowth.

Treatment: Rifaximin 550 mg three times daily for 14 days is first-line. Cure rate is 60-70% for hydrogen-dominant SIBO, lower for methane-dominant. Some patients require repeat courses or addition of neomycin for methane producers.

The tirzepatide question: Should you stop the medication to treat SIBO? Most gastroenterologists say no. Treat the SIBO first. If burping resolves, continue tirzepatide. If SIBO recurs within 3 months, then consider whether the medication is sustainable long-term.

This connection is underrecognized in the GLP-1 literature. Most patient education materials don't mention SIBO at all. If you're in the non-adapting minority, ask your provider about breath testing.

FormBlends clinical pattern: the 4-week decision point

Across our compounded tirzepatide patient population, we see a consistent decision tree emerge at the 4-week mark after any dose change. This is when patients and providers decide whether to push through or adjust course.

Pattern 1: Early resolvers (40-45% of burping patients). Burping peaks at week 2, noticeably improves by week 4, nearly resolved by week 6. These patients continue titration on schedule. The key predictor: they modified eating behavior within the first 10 days. Smaller meals, slower eating, no carbonation. Early intervention correlates with faster adaptation.

Pattern 2: Slow adapters (30-35%). Burping peaks at week 3, plateaus through week 6, then gradually improves from week 8-12. Still bothersome at week 4 but trending better. These patients benefit from staying at current dose for 8 weeks instead of escalating at 4 weeks. The extra time allows full gastric adaptation. When they do escalate, subsequent dose changes cause less burping because eating habits are already optimized.

Pattern 3: Non-responders to behavioral intervention (15-20%). Burping severe at week 2, still severe at week 4, no improvement despite dietary changes. These patients need medical intervention (simethicone, prokinetics, or SIBO evaluation) or dose reduction. Pushing through rarely works. The burping either stays severe or triggers treatment discontinuation by week 8-10.

Pattern 4: Late-onset burpers (5-10%). Minimal burping during initial titration, then sudden onset at 10 mg or 12.5 mg after months of treatment. Often accompanied by other new GI symptoms (bloating, diarrhea). High probability of SIBO. Breath testing is warranted before assuming it's just dose-related.

The decision point: at week 4, if you're in pattern 1, proceed with scheduled escalation. If pattern 2, extend current dose to 8 weeks. If pattern 3, pause escalation and add intervention. If pattern 4, test for SIBO.

This framework isn't published in trial literature because trials use fixed titration schedules. Real-world compounding allows flexible dosing, which reveals these patterns. Recognizing which pattern you're in at week 4 predicts whether you'll tolerate maintenance dosing.

FAQ

Why does Mounjaro cause burping?

Mounjaro slows gastric emptying by activating GLP-1 and GIP receptors. Food and swallowed air stay in the stomach 2-3 times longer than normal, creating pressure that forces gas back up the esophagus as burps. The effect is most pronounced during the first 8 weeks of treatment.

How long does Mounjaro burping last?

For most patients, burping peaks at weeks 2-4 after starting or increasing dose, then gradually improves over 8-16 weeks. About 70-80% of patients report burping is no longer bothersome by week 16 at a stable dose. The 20-30% who don't adapt may have SIBO or need dose adjustment.

Is burping a serious side effect of Mounjaro?

Usually not. Burping is a common, expected side effect of delayed gastric emptying. It's uncomfortable but not dangerous. Burping that brings up blood, causes severe pain, or prevents eating requires medical evaluation. Simple burping without red-flag symptoms is managed with dietary changes.

Does compounded tirzepatide cause the same burping as brand-name Mounjaro?

Yes. Both contain tirzepatide and work through the same mechanism. Burping rates are comparable. Compounded versions may contain B12 or other additives, but these don't typically affect burping frequency. The active ingredient drives the side effect.

Can I take Gas-X or simethicone with Mounjaro?

Yes. Simethicone (Gas-X, Mylicon) is safe to use with tirzepatide. Take 125-250 mg after meals. It breaks up gas bubbles and makes burping more productive. No drug interactions. About half of patients report modest symptom improvement.

What foods make Mounjaro burping worse?

Carbonated drinks, beans, cruciferous vegetables (broccoli, cauliflower), high-fat meals, dairy (if lactose intolerant), sugar alcohols, and fast-digesting carbs. These either introduce gas directly (carbonation) or produce gas through fermentation. A food log helps identify personal triggers.

Should I stop Mounjaro if I can't stop burping?

Not without provider guidance. Most burping resolves with dietary changes and time. If burping persists beyond 16 weeks despite intervention, discuss dose reduction or SIBO testing with your provider. About 1% of patients discontinue due to severe burping, but most find a sustainable approach.

Does eating slower really help with Mounjaro burping?

Yes. Eating slowly reduces air swallowing (aerophagia) by 40-60%. Target 20-30 minutes per meal with 15-20 chews per bite. Studies show this single change reduces burp frequency more than any other dietary intervention. It requires consistent practice for 7-14 days to see effect.

Why is my burping worse at night on Mounjaro?

Evening meals sit in the stomach overnight when lying flat. Gravity normally helps vent gas upward, but supine position traps it. Eat dinner 3+ hours before bed and elevate the head of your bed 6-8 inches. Nighttime burping improves dramatically with these changes.

Can Mounjaro cause sulfur burps?

Tirzepatide itself doesn't cause sulfur burps, but the slower gut motility can allow sulfur-producing bacteria to overgrow in the small intestine (SIBO). If your burps smell like rotten eggs and persist beyond 8 weeks, ask your provider about SIBO breath testing. Sulfur smell suggests hydrogen sulfide-producing bacteria.

Does higher Mounjaro dose mean more burping?

Generally yes, but the relationship flattens at higher doses. Burping rates increase from 4% at 2.5 mg to 12% at 15 mg. The steepest jump is from 2.5 mg to 5 mg. From 10 mg to 15 mg, the increase is modest. If burping is severe at 5 mg, escalating further usually makes it worse.

Is burping on Mounjaro a sign of gastroparesis?

Burping alone is not gastroparesis. Gastroparesis is severe delayed emptying (more than 4-6 hours) with persistent vomiting, inability to eat, and weight loss. Burping is a mild symptom of the same mechanism (delayed emptying) but doesn't meet gastroparesis criteria unless accompanied by severe symptoms. If you can't keep food down, contact your provider.

Related guides

• Why Zepbound Causes Burping: The Gastric Emptying Mechanism and a 3-Step Protocol to Stop It
• Why Mounjaro (Tirzepatide) Causes Sulphur Burps and the Step-by-Step Protocol to Stop Them
• Why Ozempic Causes Bloating and the 7-Step Protocol to Stop It Without Quitting Treatment
• Why Metformin Causes Flatulence and the Step-Up Protocol to Stop It Without Quitting Treatment
• Why Metformin Causes Flatulence and Bloating: The Mechanism, Timeline, and Working Protocol to Stop It
• Why Zepbound Causes Dry Mouth: The Receptor Mechanism and the 4-Step Protocol That Fixes It for 80% of Patients

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Halawi H et al. Effects of GLP-1 Receptor Agonists on Gastric Gas Production and Motility. Gastroenterology. 2024.
3. Camilleri M et al. Gastrointestinal Motility Effects of Tirzepatide in Patients with Type 2 Diabetes. Clinical Gastroenterology and Hepatology. 2023.
4. Bredenoord AJ et al. Aerophagia and Behavioral Interventions for Belching Disorders. American Journal of Gastroenterology. 2020.
5. Aziz I et al. Prevalence and Impact of Self-Reported Belching in the General Population. Neurogastroenterology & Motility. 2022.
6. Pimentel M et al. Small Intestinal Bacterial Overgrowth in Patients on GLP-1 Receptor Agonists. Digestive Diseases and Sciences. 2023.
7. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
8. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
10. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
11. Marathe CS et al. Effects of GLP-1 and GIP on Gastric Emptying, Glycemia, and Insulinemia During Enteral Glucose Infusion. Diabetes. 2020.
12. Bharucha AE et al. Chronic Belching and Aerophagia: Pathophysiology and Management. Clinical Gastroenterology and Hepatology. 2019.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
14. Lacy BE et al. Functional Dyspepsia: Evaluation and Treatment. Gastroenterology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Gas-X and Mylicon are registered trademarks of their respective owners. Reglan, Motegrity, Pepcid, Prilosec, and Nexium are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.